A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects

Inclusion Criteria:

- Subjects aged 18 years or older, at the time of signing the informed consent.

- Subjects with documented physician diagnosis of asthma as their primary respiratory
disease.

- ACT score <20 at screening visit.

- Non-smokers (never smoked or not smoking for >6 months with <10 pack years history
(Pack years = [cigarettes per day smoked/20] multiplied by number of years smoked).

- Male or female subjects will be included. A female subject is eligible to participate
if she is not pregnant, not breastfeeding, and at least one of the following
conditions applies: (i) Not a woman of childbearing potential (WOCBP). (ii) A WOCBP
who agrees to follow the contraceptive guidance during the treatment period and for at
least 5 days] after the last dose of study treatment.

- Capable of giving signed informed consent which includes compliance with the
requirements and restrictions listed in the consent form and protocol.

- Subject understands and is willing, able, and likely to comply with study procedures
and restrictions.

- Subject must be able to read in a language supported by the smart phone app in their
region.

- Subject must have been on maintenance therapy (Fixed dose combination ICS/LABA) for 3
months, cannot have changed dose in the month prior to screening and be able to change
to an equivalent dose of RELVAR/BREO for the duration of the study. Other background
asthma medication such as anti-leukotrienes and oral corticosteroids are permitted
provided the dose has been stable for 1 month prior to screening.

- Subject must be able to change to Salbutamol/Albuterol MDI rescue for the duration of
the study and judged capable of withholding albuterol/salbutamol for at least 6 hours
prior to study visits.

- Subject must have their own Android or iPhone operating system (IOS) smart phone and a
data package suitable for the installation and running of the app and sending and
receiving data. Data used by the CIS is approximately 1 megabyte (MB) per month as a
maximum; this is less data than a 1 minute video streamed from YouTube (2MB).

- Subjects must be willing and able to download the app on their personal smart phone
and keep it turned on for the duration of the study. This will also require Bluetooth
to be turned on for duration of the study. Subjects will also have to turn on mobile
data for the app for the duration of study; unless travelling and when extra data
roaming costs could be incurred.

Inclusion criteria for randomization:

- ACT score <20 at randomization visit (visit 2).

Exclusion Criteria:

- Subjects with a known or suspected alcohol or drug abuse which in the opinion of the
investigator could interfere with the subject's proper completion of the protocol
requirement.

- History of life threatening asthma: Defined as an asthma episode that required
intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic
seizures within the last 6 months.

- A lower respiratory tract infection within 7 days of the screening visit.

- Concurrent diagnosis of chronic obstructive pulmonary disease (COPD) or other
respiratory disorders including active tuberculosis, lung cancer, bronchiectasis,
sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or
other active pulmonary diseases.

- History of hypersensitivity/intolerance to any components of the study inhalers
(example, lactose, magnesium stearate). In addition, subjects with a history of severe
milk protein allergy that, in the opinion of the study physician, contraindicates
participation will also be excluded.

- Historical or current evidence of clinically significant or rapidly progressing or
unstable cardiovascular, neurological, cardiovascular, neurological, renal, hepatic,
immunological, endocrine (including uncontrolled diabetes or thyroid disease) or
hematological abnormalities that are uncontrolled. Significant is defined as any
disease that, in the opinion of the investigator, would put the safety of the subject
at risk through participation, or which would affect the analysis if the
disease/condition exacerbated during the study.

- Subjects who have ever received treatment with biological based therapy example,
omalizumab, mepolizumab, for asthma.

- Subjects who have received an investigational drug and/or medical device within 30
days of entry into this study (Screening), or within five drug half-lives of the
investigational drug, whichever is longer.

- A subject will not be eligible for this study if he/she is an immediate family member
of the participating investigator, sub-investigator, study coordinator, employee of
the participating investigator, or any family member of a Propeller Health employee.